Speaker illustration

Doctor Verena Karsten

Cambridge ()

Impact of patisiran on norfolk QOL-DN in patients with hereditary transthyretin-mediated amyloidosis: results from the cardiac subpopulation in the phase 3 apollo study

Event: Heart Failure 2018 & World Congress on Acute Heart Failure

Topic: Pharmacotherapy

Session: Patient management - From oral treatment to transplant

Thumbnail

This platform is supported by

logo Novo Nordisk